Active Biotech Interim report January – September 2019


Third quarter in brief

  • A new business plan for laquinimod and tasquinimod, based on the extensive preclinical and clinical data previously generated, is in progress
  • Data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease was presented at the International congress of Parkinson’s disease and movement disorders

Events after the end of the period

  • The first patient in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors has been dosed
  • Preclinical data on naptumomab estafenatox was presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Financial summary

MSEK Jul-Sep Jan-Sep Full-Year
  2019 2018 2019 2018 2018
Net sales 0,9 4,7 7,5 15,2 20,1
Operating loss -9,3 -6,9 -21,1 -22,8 -29,8
Loss after tax -9,3 -8,7 -22,9 -28,0 -36,9
Earnings per share (SEK) -0,06 -0,06 -0,16 -0,21 -0,27
Cash and cash equivalents (at close of period)     69,9 36,0 25,6

For further information, please contact:

  Helén Tuvesson, CEO
  Tel: +46 (0)46 19 21 56


  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00

The report is also available at .

Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on November 14, 2019 at 08.30 a.m. CET. 


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Aducanumab is good; next generation Alzheimer’s disease therapies will be better5.12.2019 18:50:00 CETPress release

New data for aducanumab strengthens potential for Alzheimer’s therapy in near term, fuels next-generation therapies with more selective binding for toxic species of amyloid beta TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen for its trailblazing efforts to advance aducanumab. Data released today at CTAD (Clinical Trials on Alzheimer’s Disease conference) strengthen aducanumab’s potential to become the first disease-modifying therapy for Alzheimer’s disease. The data clearly underscore the need for next-generation drug candidates that offer more precise binding to the misfolded beta amyloid oligomer (AßO), the toxic species of the amyloid beta protein and root cause of Alzheimer’s disease. “Today’s presentation reflects yet ano

Olainfarm invites to Third Quarter 2019 Investor Conference Webinar5.12.2019 18:17:00 CETPress release

JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on December 11, 2019 at 16:00 (EET). To join the webinar please follow the instructions below. Webinar will be hosted by the Chairman of Management Board Jeroen Weites and Investor Relations Advisor Janis Dubrovskis. The presentation will be held in English. During the webinar JSC Olainfarm representatives will inform about the recent performance of the company and financial results of third quarter and 9 months of 2019. After the presentation investors are welcome to ask questions. Due to the limited webinar time please send in your questions in advance to e-mail: What is a webinar? Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask questions and get answe

Rockridge Receives Exploration Permit for its Raney Gold Project; Planning Drilling Program in Early 20205.12.2019 14:00:00 CETPress release

VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd. (TSX-V: ROCK) (“Rockridge” or the “Company”) is pleased to announce that it has received an Exploration Permit for its Raney Gold Project located in Ontario, Canada (the “Raney Gold Project” or “Property”). The permit provides for exploration activities including geophysical surveys and diamond drilling to be conducted over a 3-year period. Highlights: Rockridge option to earn a 100% interest in the Raney Gold Project Prospective gold property located ~110 km south west of the prolific gold district of Timmins, ON Limited historical exploration campaigns conducted on the Property; the last exploration activities occurred ~10 years ago when gold prices were in the US$900/oz. range Follow-up on historical drill results, best intercept returned ~6.5 g/t gold over 8m, open for expansion Planning initial ~2,500 metre drilling program in February – April 2020; potential to discover additional gold bearing

Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes5.12.2019 12:00:00 CETPress release

Press release 5 December 2019 Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes Svensk Hypotekspension Fond 3 AB (publ) (the “Issuer”) informs that it intends to voluntarily redeem the SEK 2,000,000,000 Mortgage Backed Fixed Rate Notes with ISIN SE0007691621 (the “Notes”) before the first call date in accordance with the terms and conditions originally dated 6 February 2016 and as amended and restated 27 November 2019 (the “Terms and Conditions”). All outstanding Notes will be redeemed in full at their nominal amount, together with accrued but unpaid interest and an early call premium. The redemption date is expected to be 17 December 2019 (the “Redemption Date”). A notice of early redemption will today be circulated to the holders of the Notes and will be published on the website of the Issuer. The notice will be irrevocable but conditional upon the Issuer’s receipt of satisfactory evidence that the Issuer’s affiliate Svensk Hypotekspension Fond 4 AB (publ)’s notes w

Svensk Hypotekspension Fond 3 AB (publ) – Tidig inlösen av obligation5.12.2019 12:00:00 CETPressemelding

Pressmeddelande den 5 december 2019 Svensk Hypotekspension Fond 3 AB (publ) – Tidig inlösen av obligation Svensk Hypotekspension Fond 3 AB (publ) (”Emittenten”) informerar att de avser att frivilligt lösa in de SEK 2 000 000 000 bolånesäkrade fastränteobligationerna med ISIN SE0007691621 (”Obligationerna”) före den första inlösendagen i enlighet med obligationsvillkoren, ursprungligen daterade den 6 februari 2016 och såsom ändrade och reviderade den 27 november 2019 (”Villkoren”). Samtliga utestående Obligationer kommer att lösas in till sitt nominella belopp, tillsammans med upplupen men obetald ränta och en premie för tidigt inlösen. Inlösendagen förväntas vara den 17 december 2019 (”Inlösendagen”). Ett meddelande om tidig inlösen kommer idag att cirkuleras till innehavare av Obligationerna och meddelandet kommer att publiceras på Emittentens hemsida. Meddelandet kommer att vara oåterkalleligt men villkorat av att Emittenten har tagit emot tillfredsställande bevis över att Emittenten